OnCore Login

Return to Trial Database

GU07-122

A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Status

Study Completed

Cancer Type(s)

Bladder

Study Contact

Publications

Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC)
  • B Knudsen, NM Hahn, S Daneshmand, EM Posadas, S Muhanty, SP Lerner, G Sonpavde
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB)
  • N Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, AS Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity
  • NM Hahn, BS Knudsen, S Daneshmand, MO Koch, R Bihrle, RS Foster, TA Gardner, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CL Corless, AS Alva, SS Shen, F Huang, A Gertych, GE Gallick, J Mallick, C Ryan, MD Galsky, SP Lerner, EM Posadas, G Sonpavde

Trial Locations

All sites in which the trial GU07-122 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278